1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
1
Active Trials
200 recruiting
2
Rare Diseases
across 4 areas
11
News (30d)
Trending
Eikonoklastes Therapeutics, Inc. is a company with 1 orphan drug designation across 2 rare diseases. Active clinical trials in 1 indication. 11 news articles in the past 30 days.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| amyotrophic lateral sclerosis | AAV9-Synapsin-Caveolin-1 | Des.TrialAppr. |
| brain neoplasm | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
11
overlap in 2+ diseases
0/2
candidate diseases
12
avg importance: 65
0
affecting portfolio
0% of portfolio targets high unmet need diseases
11
overlap in 2+ diseases
0/2
candidate diseases
12
avg importance: 65
0
affecting portfolio